NP-178 Becomes Algernon’s Lead Candidate for Treating IBD

NP-178 Becomes Algernon’s Lead Candidate for Treating IBD
NP-178 (emoxypine), an oral small molecule being repurposed by Algernon Pharmaceuticals, has become the company's lead candidate to treat inflammatory bowel disease (IBD). Emoxypine is one of the most commercialized generic medications in Russia and Ukraine for the treatment of several neurological disorders. Its branded form, sold under the name Mexidol, is currently being tested in a Phase 3 trial (NCT02793687) sponsored by Pharmasoft, a Russian pharmaceutical company, for the treatment of ischemic stroke. Algernon, a pharmaceutical company focused on repurposing generic medications that are not available in the U.S. or E.U., has been investigating if NP-178 could be used to treat Crohn’s disease (CD) and ulcerative colitis (UC). Of note, drug repurposing refers to the process of testing a medication with established safety in conditions other than those for which it was originally intended. Findings from the company's two recent preclinical studies, one focused on UC and the other on CD, have shown that NP-178 had strong clinical activity in diseased animals, leading to significant improvements in disease activity, body weight, stool consistency, colon length, and occult positivity (presence of unseen blood in the stool). Algernon st
Subscribe or to access all post and page content.